Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors

BMC Medical Genomics

Volumn 6, Issue 1, 2013, Pages

  Anaka, Matthew ^a,b   Hudson, Christopher ^a   Lo, Pu Han ^a   Do, Hongdo ^b,c   Caballero, Otavia L ^d   Davis, Ian D ^a,e   Dobrovic, Alexander ^b,c   Cebon, Jonathan ^a,b,f   Behren, Andreas ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EASTERN HEALTH   (Australia)

^f LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Clonal; Copy number; Heterogeneity; Melanoma; Microarray; Mutation profiling

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; SCATTER FACTOR RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER RESISTANCE; CELL CLONE; CELL SURVIVAL; CHROMOSOME 1; CHROMOSOME 13; CHROMOSOME 19; CLINICAL ARTICLE; CLONAL VARIATION; CLONOGENESIS; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE ACTIVITY; GENE AMPLIFICATION; GENE CLUSTER; GENE DELETION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE INDUCTION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; METASTATIC MELANOMA; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR GROWTH;

CELL LINE, TUMOR; CLONE CELLS; DNA COPY NUMBER VARIATIONS; FEMALE; GENETIC VARIATION; HUMANS; MALE; MELANOMA; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTOME;

EID: 84885333035     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-6-40     Document Type: Article

References (29)

1. The multistep nature of cancer. Vogelstein B, Kinzler KW, Trends Genet 1993 9 138 141 10.1016/0168-9525(93)90209-Z 8516849 (Pubitemid 23098782)
2. Cancer as an evolutionary and ecological process. Merlo LM, Pepper JW, Reid BJ, Maley CC, Nat Rev Cancer 2006 6 924 935 10.1038/nrc2013 17109012 (Pubitemid 44862677)
3. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ, Nat Genet 2006 38 468 473 10.1038/ng1768 16565718
4. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, et al. Nature 2010 467 1114 1117 10.1038/nature09515 20981102
5. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. N Engl J Med 2012 366 883 892 10.1056/NEJMoa1113205 22397650
6. Melanoma genome sequencing reveals frequent PREX2 mutations. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, et al. Nature 2012 485 502 506 22622578
7. A landscape of driver mutations in melanoma. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, et al. Cell 2012 150 251 263 10.1016/j.cell.2012.06.024 22817889
8. Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Sabatino M, Zhao Y, Voiculescu S, Monaco A, Robbins P, Karai L, Nickoloff BJ, Maio M, Selleri S, Marincola FM, Wang E, Cancer Res 2008 68 122 131 10.1158/0008-5472.CAN-07-1939 18172304 (Pubitemid 351380113)
9. Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis. Takata M, Morita R, Takehara K, Int J Cancer 2000 85 492 497 10.1002/(SICI)1097-0215(20000215)85:4<492::AID-IJC8>3.0. CO;2-# 10699920 (Pubitemid 30075126)
10. Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. Fusi A, Berdel R, Havemann S, Nonnenmacher A, Keilholz U, Eur J Cancer 2011 47 1971 1976 10.1016/j.ejca.2011.04.013 21570823
11. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, Lo RS, Kefford RF, Scolyer RA, Long GV, Mol Cancer Ther 2012 11 2704 2708 10.1158/1535-7163.MCT-12-0530 22962325
12. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferre F, et al. Nature 2011 471 513 517 10.1038/nature09806 21430779
13. Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Macgregor S, Montgomery GW, Liu JZ, Zhao ZZ, Henders AK, Stark M, Schmid H, Holland EA, Duffy DL, Zhang M, et al. Nat Genet 2011 43 1114 1118 10.1038/ng.958 21983785
14. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Luker KE, Pica CM, Schreiber RD, Piwnica-Worms D, Cancer Res 2001 61 6540 6547 11522652 (Pubitemid 32783262)
15. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, Namiki M, Prostate 2007 67 955 967 10.1002/pros.20581 17440963 (Pubitemid 46828929)
16. Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer. Kreso A, O'Brien CA, van Galen P, Gan O, Notta F, Brown AM, Ng K, Ma J, Wienholds E, Dunant C, et al. Science 2012 339 543 548 23239622
17. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al. Nature 2012 486 537 540 22722843
18. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al. Cancer Cell 2010 18 683 695 10.1016/j.ccr.2010.11.023 21156289
19. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA, Rivoltini L, et al. Neoplasia 2011 13 1132 1142 22241959
20. MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma. Gibbs P, Hutchins AM, Dorian KT, Vaughan HA, Davis ID, Silvapulle M, Cebon JS, Melanoma Res 2000 10 259 264 10890380
21. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Moorhead M, Wang ZC, Richardson AL, Warren R, Walther A, et al. BMC Med Genomics 2009 2 8 10.1186/1755-8794-2-8 19228381
22. Limma: linear models for microarray data. Smyth GK, Bioinformatics and Computational Biology Solutions using R and Bioconductor New York: Springer, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, 2005 397 420
23. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Proc Natl Acad Sci USA 2005 102 15545 15550 10.1073/pnas.0506580102 16199517 (Pubitemid 41528093)
24. Performance comparison of benchtop high-throughput sequencing platforms. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, Pallen MJ, Nat Biotechnol 2012 30 434 439 10.1038/nbt.2198 22522955
25. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F, Bioinformatics 2010 26 2069 2070 10.1093/bioinformatics/btq330 20562413
26. SIFT web server: predicting effects of amino acid substitutions on proteins. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC, Nucleic Acids Res 2012 40 452 W457 10.1093/nar/gks539 22689647
27. A method and server for predicting damaging missense mutations. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR, Nat Methods 2010 7 248 249 10.1038/nmeth0410-248 20354512
28. Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Do H, Dobrovic A, Oncotarget 2012 3 546 558 22643842
29. Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies. Do H, Dobrovic A, Mol Cancer 2009 8 82 10.1186/1476-4598-8-82 19811662